Brief: Apollomics Inc. Doses First Patient In Phase 3 Clinical Trial In China Of Glycomimetics’ Uproleselan For The Treatment Of Aml
23/11/2021 21:48
Nov 23 (Reuters) - GlycoMimetics Inc GLYC.O :
* APOLLOMICS INC. DOSES FIRST PATIENT IN PHASE 3 CLINICAL
TRIAL IN
CHINA OF GLYCOMIMETICS’ UPROLESELAN FOR THE TREATMENT OF AML
Source text for Eikon: ID:nBw7XzSSba
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering